Fatty acid amide hydrolase inhibitors of the Formula:
##STR00001##
I. are provided wherein X is NH, CH.sub.2, O, or S; Q is O or S; Z is O or
N; R is an aromatic moiety selected from the group consisting of
substituted or unsubstituted aryl; substituted or unsubstituted
biphenylyl, substituted or unsubstituted naphthyl, and substituted or
unsubstituted phenyl; substituted or unsubstituted terphenylyl;
substituted or unsubstituted cycloalkyl, heteroaryl, or alkyl; and
R.sub.1 and R.sub.2 are independently selected from the group consisting
of H, substituted or unsubstituted alkyl, substituted or unsubstituted
heteroalkyl, and substituted or unsubstituted phenyl, substituted or
unsubstituted biphenylyl, substituted or unsubstituted aryl, and
substituted or unsubstituted heteroaryl; with the proviso that if Z is O,
one of R.sub.1 and R.sub.2 is absent, and that if Z is N, optionally
R.sub.1 and R.sub.2 may optionally be taken together to form a
substituted or unsubstituted N-heterocycle or substituted or
unsubstituted heteroaryl with the N atom to which they are each attached.
Pharmaceutical compositions comprising the compounds of Formula I and
methods of using them to inhibit FAAH and/or treat appetite disorders,
glaucoma, pain, insomnia, and neurological and psychological disorders
including anxiety disorders, epilepsy, and depression are provided.